Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Neurim Pharmaceuticals Ltd - Product Pipeline Review - 2015

Published: Feb-2015 | Format: PDF | Global Markets Direct | Number of pages: 35 | Code: MRS - 7038

 

Global Markets Direct’s, ‘Neurim Pharmaceuticals Ltd Product Pipeline Review 2015’, provides an overview of the Neurim Pharmaceuticals Ltd’s pharmaceutical research and development focus.

 

This report provides comprehensive information on the current therapeutic developmental pipeline of Neurim Pharmaceuticals Ltd’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

 

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

The report provides brief overview of Neurim Pharmaceuticals Ltd including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of Neurim Pharmaceuticals Ltd’s human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement 
Latest news and deals relating to the Neurim Pharmaceuticals Ltd’s pipeline products

 

Reasons to buy

 

Evaluate Neurim Pharmaceuticals Ltd’s strategic position with total access to detailed information on its product pipeline
Assess the growth potential of Neurim Pharmaceuticals Ltd in its therapy areas of focus
Identify new drug targets and therapeutic classes in the Neurim Pharmaceuticals Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of Neurim Pharmaceuticals Ltd and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neurim Pharmaceuticals Ltd
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of Neurim Pharmaceuticals Ltd and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues

Table of Contents
 

 

Table of Contents 2
List of Tables 4
List of Figures 4
Neurim Pharmaceuticals Ltd Snapshot 5
Neurim Pharmaceuticals Ltd Overview 5
Key Information 5
Key Facts 5
Neurim Pharmaceuticals Ltd - Research and Development Overview 6
Key Therapeutic Areas 6
Neurim Pharmaceuticals Ltd - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Neurim Pharmaceuticals Ltd - Pipeline Products Glance 11
Neurim Pharmaceuticals Ltd - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Neurim Pharmaceuticals Ltd - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Neurim Pharmaceuticals Ltd - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Neurim Pharmaceuticals Ltd - Drug Profiles 15
melatonin ER 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
piromelatine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Neu-120 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Neu-107 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Neu-164 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Neu-240 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Neu-AZ1 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
NeuP-12 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Neurim Pharmaceuticals Ltd - Pipeline Analysis 25
Neurim Pharmaceuticals Ltd - Pipeline Products by Target 25
Neurim Pharmaceuticals Ltd - Pipeline Products by Route of Administration 27
Neurim Pharmaceuticals Ltd - Pipeline Products by Molecule Type 28
Neurim Pharmaceuticals Ltd - Pipeline Products by Mechanism of Action 29
Neurim Pharmaceuticals Ltd - Recent Pipeline Updates 30
Neurim Pharmaceuticals Ltd - Dormant Projects 32
Neurim Pharmaceuticals Ltd - Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33

 

Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35"


 

List of Tables
 

 

Neurim Pharmaceuticals Ltd, Key Information 5
Neurim Pharmaceuticals Ltd, Key Facts 5
Neurim Pharmaceuticals Ltd - Pipeline by Indication, 2015 8
Neurim Pharmaceuticals Ltd - Pipeline by Stage of Development, 2015 9
Neurim Pharmaceuticals Ltd - Monotherapy Products in Pipeline, 2015 10
Neurim Pharmaceuticals Ltd - Phase III, 2015 11
Neurim Pharmaceuticals Ltd - Phase II, 2015 12
Neurim Pharmaceuticals Ltd - Phase I, 2015 13
Neurim Pharmaceuticals Ltd - Preclinical, 2015 14
Neurim Pharmaceuticals Ltd - Pipeline by Target, 2015 26
Neurim Pharmaceuticals Ltd - Pipeline by Route of Administration, 2015 27
Neurim Pharmaceuticals Ltd - Pipeline by Molecule Type, 2015 28
Neurim Pharmaceuticals Ltd - Pipeline Products by Mechanism of Action, 2015 29
Neurim Pharmaceuticals Ltd - Recent Pipeline Updates, 2015 30
Neurim Pharmaceuticals Ltd - Dormant Developmental Projects,2015 32
Neurim Pharmaceuticals Ltd, Subsidiaries 33"


 

List of Figures
 

 

Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Indication, 2015 7
Neurim Pharmaceuticals Ltd - Pipeline by Stage of Development, 2015 9
Neurim Pharmaceuticals Ltd - Monotherapy Products in Pipeline, 2015 10
Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Target, 2015 25
Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Route of Administration, 2015 27
Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Molecule Type, 2015 28
Neurim Pharmaceuticals Ltd - Pipeline Products by Top 10 Mechanism of Action, 2015 29

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)1500 View Pricing